MESO Stock Analysis: Buy, Sell, or Hold?
MESO - Mesoblast Limited American Depositary Shares
$15.22
-0.11 (-0.72%)
▼
5d:
-5.93%
30d:
+5.99%
90d:
-20.61%
HOLD
LOW Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 29, 2026
29d
Get Alerted When MESO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MESO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: MESO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: MESO is currently trading at $15.22, which is considered fair relative to its 30-day fair value range of $14.35 to $15.90. From a valuation perspective, the stock is trading at a discount (Forward PE: -217.4) compared to its historical average (206.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MESO is in a strong downtrend. The price is currently testing key support at $15.18. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.00 (+130.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MESO is in a strong downtrend. The price is currently testing key support at $15.18. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.00 (+130.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$14.35 -
$15.90
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.0% below Wall St target ($35.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -5.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$14.35 -
$15.90
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$15.18
Resistance Level
$16.89
Current Trend
Strong Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-217.43
Wall Street Target
$35.00
(+130.0%)
Revenue Growth (YoY)
1526.8%
Profit Margin
-144.3%
PE vs Historical
-217.4 vs 206.7
CHEAP
Share & Embed Analysis
Last updated: April 29, 2026 7:43 AM ET
Data refreshes hourly during market hours. Next update: 8:43 AM
Data refreshes hourly during market hours. Next update: 8:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MESO showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gregory George
BUY
2324072 shares
2026-04-10
Gregory George
BUY
1586890 shares
2026-04-09
Gregory George
BUY
1981890 shares
2026-04-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$27 | 57 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$131 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 53 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 53 HOLD |
